

PATENT APPLICATION
PO-8232-1
RC-235

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF)
TORSTEN ZISER ET AL) GROUP NO.: 1796
SERIAL NUMBER: 10/573,374) CONFIRMATION NO.: 2733
FILED: MARCH 24, 2006) EXAMINER: CHUN CHENG WANG
TITLE: MICROGELS IN NON-CROSSLINKABLE)
ORGANIC MEDIA)

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 and 1.98

Dear Sir or Madam:

Applicants submit herewith patents, publication and/or other information of which they are aware, in accordance with 37 CFR §1.56(b), to the examination of this application. Please consider the references on the enclosed PTO-1449 forms.

It is requested that the Examiner consider these references and officially make them of record in accordance with the provisions of 37 CFR §1.97 and §609 of the MPEP. While the information referred to in this Information Disclosure Statement may be relevant to the examination pursuant to 37 CFR §1.97(h), the filing "shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56(b)." Pursuant to 37 CFR §1.97(g), the filing "shall not be construed as a representation that a search has been made" or that no other material information exists.


The USPTO is hereby authorized to charge the fees indicated, and any additional fees or those under 37 C.F.R. §1.16 or 1.17, which may be required by this paper, and/or to credit any overpayments to Deposit Account No. 50-2527.

CERTIFICATE OF TRANSMISSION BY EFS-Web

I hereby certify that this paper is being transmitted to the U.S. Patent and Trademark Office via EFS-Web on February 1, 2010.

Anne B. Edgar

Name of person transmitting paper or fee



Signature

1. [] This Information Disclosure Statement is filed within the period set forth in 37 CFR §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, which ever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 CFR §1.17 or credit any overpayment to Deposit Account 50-2527.

2. [X] This Information Disclosure Statement is filed within the period set forth in 37 CFR §1.97(c) because it is filed after the period set forth in 37 CFR §1.97(b) but it is believed to be filed before the mailing date of a final office action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

[] (a) I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

[] (b) I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or

[X] (c) The Commissioner is authorized to charge any fees under 37 CFR §1.17 or credit any overpayment to Deposit Account 50-2527.

3. [] This Information Disclosure Statement is filed within the period set forth in 37 CFR §1.97(d) because it is filed after the period set forth in 37 CFR §1.97(c) but it is believed to be filed after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee.

[] (a) I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

[] (b) I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and

[] (c) The Commissioner is authorized to charge any fees under 37 CFR §1.17 or credit any overpayment to Deposit Account 50-2527

[] (d) This filing is being made with the filing of Request for Continued Examination. No fee under 37 CFR §1.17 is required.

4. [X] For each of the items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation or abstract of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed.

Respectfully submitted,



By:

Nicanor A. Kohncke
Attorney for Applicants
Registration No. 57,348

LANXESS Corporation
Law & Intellectual Property Department
111 RIDC Park West Drive
Pittsburgh, Pennsylvania 15275
Phone: (412) 809-2234
Facsimile: (412) 809-1054

\sr\S:\Law Shared\SHARED\PATENTS\8000-8999\8232-1\IDSSupplementalArt_020110.doc